Anti-osteoporotic effect of sitagliptin in an osteoporosis model of ovariectomized rats: role of RUNX2 and RANKL/OPG ratio
- PMID: 40397119
- DOI: 10.1007/s00210-025-04145-4
Anti-osteoporotic effect of sitagliptin in an osteoporosis model of ovariectomized rats: role of RUNX2 and RANKL/OPG ratio
Abstract
This study examines the potential anti-osteoporotic effect of sitagliptin in osteoporosis instigated by ovariectomy (OVX) in rats. Rats were assigned into 4 groups: Sham-operated, OVX group, and OVX rats orally treated with sitagliptin (10, 20 mg/kg), respectively, after 8 weeks of OVX for 4 weeks. Biochemical, real-time polymerase chain reaction, histopathological, and immunohistochemical analyses of bone resorption and formation were conducted. Sitagliptin ameliorated bone mineral density (BMD), restored calcium and phosphorus levels in OVX rats, elevated catalase and decreased malondialdehyde, reduced receptor activator of NF-κB ligand (RANKL), elevated osteoprotegerin (OPG), and reduced tartrate-resistant acid phosphatase (TRAP) femur contents. Sitagliptin mitigated variations in mRNA expressions of RUNX2 and protein kinase B (AKT) in femur tissue. Moreover, sitagliptin reduced caspase-3 protein expression and improved bone histomorphology and mechanical properties. Sitagliptin's anti-oxidant activity mediated its anti-osteoporotic effect in OVX rats via modulation of RUNX2, downregulation of RANKL/OPG, AKT pathways, apoptosis, and histomorphometry alterations revealing attenuation of osteoclastogenesis and promotion of osteoblast formation.
Keywords: Ovariectomy; RANKL/OPG; RUNX2; Rats; Sitagliptin; TRAP.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethical approval: All animal procedures adhered to the ARRIVE guidelines and received approval from the Ethical Committee of Medical Research, National Research Centre, no. 14110112021. Consent to participate: N/A. Consent for publication: N/A. Competing interests: The authors declare no competing interests.
Similar articles
-
Rehmanniae Radix Preparata suppresses bone loss and increases bone strength through interfering with canonical Wnt/β-catenin signaling pathway in OVX rats.Osteoporos Int. 2019 Feb;30(2):491-505. doi: 10.1007/s00198-018-4670-y. Epub 2018 Aug 27. Osteoporos Int. 2019. PMID: 30151623
-
Effect of Zuoguiwan on osteoporosis in ovariectomized rats through RANKL/OPG pathway mediated by β2AR.Biomed Pharmacother. 2018 Jul;103:1052-1060. doi: 10.1016/j.biopha.2018.04.102. Epub 2018 Apr 25. Biomed Pharmacother. 2018. PMID: 29710663
-
Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway.Acta Pharmacol Sin. 2012 Apr;33(4):479-89. doi: 10.1038/aps.2011.177. Epub 2012 Mar 19. Acta Pharmacol Sin. 2012. PMID: 22426695 Free PMC article.
-
Genistein and Silicon Synergistically Protects Against Ovariectomy-Induced Bone Loss Through Upregulating OPG/RANKL Ratio.Biol Trace Elem Res. 2019 Apr;188(2):441-450. doi: 10.1007/s12011-018-1433-8. Epub 2018 Jul 16. Biol Trace Elem Res. 2019. PMID: 30014283
-
Syringin prevents bone loss in ovariectomized mice via TRAF6 mediated inhibition of NF-κB and stimulation of PI3K/AKT.Phytomedicine. 2018 Mar 15;42:43-50. doi: 10.1016/j.phymed.2018.03.020. Epub 2018 Mar 12. Phytomedicine. 2018. PMID: 29655696
References
-
- Abu-Elala NM, Abd-Elsalam RM, Marzouk MS (2015) Molecular and immunohistochemical diagnosis of Photobacterium damselae subspecies piscicida during naturally occurring disease in Egypt. J World Aquacult Soc 46:583–595 - DOI
-
- Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121–126. https://doi.org/10.1016/s0076-6879(84)05016-3 - DOI - PubMed
-
- Arafa EA, Elgendy NO, Elhemely MA, Abdelaleem EA, Mohamed WR (2023) Diosmin mitigates dexamethasone-induced osteoporosis in vivo: role of Runx2, RANKL/OPG, and oxidative stress. Biomed Pharmacother 161:114461. https://doi.org/10.1016/j.biopha.2023.114461 - DOI - PubMed
-
- Chen D, Wang Q, Li Y, Sun P, Kuek V, Yuan J, Yang J, Wen L, Wang H, Xu J, Chen P (2021) Notopterol Attenuates estrogen deficiency-induced osteoporosis via repressing RANKL signaling and reactive oxygen species. Front Pharmacol 12:664836. https://doi.org/10.3389/fphar.2021.664836 - DOI - PubMed - PMC
-
- Cheng Y, Liu P, Xiang Q, Liang J, Chen H, Zhang H, Yang L (2022b) Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway. BMC Musculoskelet Disord 23:465. https://doi.org/10.1186/s12891-022-05396-5 - DOI - PubMed - PMC
LinkOut - more resources
Full Text Sources
Research Materials